Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer (ELITE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05181826 |
Recruitment Status :
Recruiting
First Posted : January 6, 2022
Last Update Posted : July 11, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Cancer Liver Cirrhosis Chronic Hepatitis Hepatitis B Hepatitis C Diabetes COPD | Diagnostic Test: Multi-analyte Blood Test |
Study Type : | Observational |
Estimated Enrollment : | 1200 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Official Title: | Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer |
Actual Study Start Date : | May 21, 2019 |
Estimated Primary Completion Date : | September 2023 |
Estimated Study Completion Date : | December 2023 |
- Diagnostic Test: Multi-analyte Blood Test
Intend for the qualitative detection of DNA methylation markers for the detection of various types of cancer
- Independent performance measure of sensitivity and specificity of a multi-analyte blood test [ Time Frame: 1 month ]The primary objective is to measure the performance (sensitivity and specificity) the multi-analyte blood Test for the detection of liver cancers in healthy subjects, subjects diagnosed with active cancer, subjects in cancer remission, and subjects diagnosed with a benign disease.
- To investigate potential endogenous and exogenous interfering substances of a multi-analyte blood test [ Time Frame: 1 Month ]To investigate potential endogenous and exogenous interfering substances of a multi-analyte blood test for the detection of liver cancers within healthy subjects, subjects diagnosed with active cancer, subjects in cancer remission, and subjects diagnosed with a benign disease.
- Ascertain Reference Range(s) [ Time Frame: 1 Month ]Ascertain reference range determination(s) for select CpG methylation sites
- Ascertain Sample Stability [ Time Frame: 1 Month ]Sample stability under various shipping conditions
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
2.1.1 Age 18 years or older.
2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. .
Exclusion Criteria:
2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded.
2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05181826
Contact: Clinical Operations Manager | 6263500537 | octavia@heliogenomics.com |
United States, California | |
Torrance Memorial Physician Network - Cancer Care | Active, not recruiting |
Redondo Beach, California, United States, 90277 | |
United States, Minnesota | |
Allina Health, Virginia Piper Cancer Institute | Recruiting |
Coon Rapids, Minnesota, United States, 55433 | |
Contact: Kathryn Gruetzman 763-236-0814 kathryn.gruetzman@allina.com | |
Principal Investigator: Micheala Tsai, MD | |
Virginia Piper Cancer Institute Mercy Hospital-Unity Campus | Recruiting |
Fridley, Minnesota, United States, 55432 | |
Contact: Lynne Schroeder lynne.schroeder@allina.com | |
Principal Investigator: Micheala Tsai | |
VPCI Oncology Research | Recruiting |
Minneapolis, Minnesota, United States, 55407 | |
Contact: Kelsey Froemming kelsey.froemming@allina.com | |
Principal Investigator: Micheala Tsai, MD | |
United States, Tennessee | |
Methodist LeBonheur Healthcare | Recruiting |
Memphis, Tennessee, United States, 38104 | |
Contact: Carol Jones 901-516-8078 carol.jones@mlh.org | |
Principal Investigator: Jiten Kothadia, MD | |
United States, Texas | |
Liver Center of Texas | Recruiting |
Dallas, Texas, United States, 75234 | |
Contact: Ariela Moreno ariela@livercenteroftexas.com | |
Principal Investigator: Abdullah Mubarak, MD | |
Methodist Hospital | Recruiting |
Richardson, Texas, United States, 75082 | |
Contact: Araceli Torres aracelitorres@mhd.com | |
Principal Investigator: Rohan Jeyarajah, MD |
Study Director: | Taggert | Helio Health |
Responsible Party: | Helio Genomics |
ClinicalTrials.gov Identifier: | NCT05181826 |
Other Study ID Numbers: |
001-2018 |
First Posted: | January 6, 2022 Key Record Dates |
Last Update Posted: | July 11, 2023 |
Last Verified: | July 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
DNA Virus Infections Hepatitis A Hepatitis C Hepatitis B Hepatitis Liver Cirrhosis Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases |
Infections Enterovirus Infections Picornaviridae Infections RNA Virus Infections Blood-Borne Infections Communicable Diseases Flaviviridae Infections Hepadnaviridae Infections Pathologic Processes Fibrosis |